Shame and Exculpation: Integration Modeling and Neuroimaging Approaches to Social Emotions

Imagine just winning the lottery. How much would you give to friends and acquaintances? Would your choice be different if no one knew you had just won? For many people, choices depend upon not only the material outcomes involved, but also on the beliefs and expectations of other people. Violation of these social expectations may result in negative emotions such as shame. Here we study behavior and neural responses to such expectations in the context of a simple economic game—the stochastic dictator game. In the game, a dictator chooses to allocate money between herself and an anonymous recipient while the pot of money available varies across rounds. Crucially, whereas the dictator always knows the pot size, the recipient can find out only with some probability. Behaviorally, we found that dictators gave more to the recipient when there was a greater likelihood of the recipient finding out the true pot size. In addition, subjects indicated a preference to hide the pot size from the recipient when it was large, but to reveal when the pot size was small. Using a model-based approach, we characterized subjects’ preferences as a weighted combination of material payoffs, payoff inequity, and the risk of being shamed. Functional neuroimaging showed that shame risk was negatively correlated with activity in the medial prefrontal cortex, whereas the relief of shame was positively correlated with activity in the striatum. Taken together, these results shed light on the cognitive processes underlying higher-order emotions, as well as their neural substrates

Significantly high polarization degree of the very low-albedo asteroid (152679) 1998 KU2_\mathrm{2}

We present a unique and significant polarimetric result regarding the near-Earth asteroid (152679) 1998 KU$_\mathrm{2}$ , which has a very low geometric albedo. From our observations, we find that the linear polarization degrees of 1998 KU$_\mathrm{2}$ are 44.6 $\pm$ 0.5\% in the R$_\mathrm{C}$ band and 44.0 $\pm$ 0.6\% in the V band at a solar phase angle of 81.0\degr. These values are the highest of any known airless body in the solar system (i.e., high-polarization comets, asteroids, and planetary satellites) at similar phase angles. This polarimetric observation is not only the first for primitive asteroids at large phase angles, but also for low-albedo (< 0.1) airless bodies. Based on spectroscopic similarities and polarimetric measurements of materials that have been sorted by size in previous studies, we conjecture that 1998 KU$_\mathrm{2}$ has a highly microporous regolith structure comprising nano-sized carbon grains on the surface.Comment: 9 pages, 5 figures, and 3 tables, accepted for publication in A&

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure : A Subanalysis of the CANDLE Trial

Background: We present results of a 24-week comparative study of the effects of the sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin vs. the sulfonylurea glimepiride, by baseline body mass index (BMI), in patients with type 2 diabetes and chronic heart failure. Methods: We conducted a post hoc analysis of the CANDLE trial. This subanalysis evaluated NT-proBNP, BMI, and other laboratory parameters, according to the subgroups stratified by BMI ≥ 25 kg/m2 vs. BMI < 25 kg/m2. Results: A group ratio of proportional changes in the geometric means of NT-proBNP was 0.99 (p = 0.940) for the subgroup with BMI ≥ 25 kg/m2 and 0.85 (p = 0.075) for the subgroup with BMI < 25 kg/m2, respectively. When baseline BMI was modeled as a continuous variable, results for patients with BMI < 30 kg/m2 showed a slightly smaller increase in NT-proBNP in the canagliflozin group vs. the glimepiride group (p = 0.295); that difference was not seen among patients with BMI ≥30 kg/m2 (p = 0.948). Irrespective of obesity, the canagliflozin group was associated with significant reduction in BMI compared to the glimepiride group. Conclusion: There was no significant difference in the effects of canagliflozin, relative to glimepiride, on NT-proBNP concentrations irrespective of baseline obesity. UMIN clinical trial registration number: UMIN000017669

Effects of canagliflozin on WBC counts

Aims/Introduction: Clinical evidence is lacking about the influence of sodium–glucose cotransporter 2 inhibitors on white blood cell (WBC) counts, a commonly used and widely available marker of inflammation. The aim of the present analysis was to assess the effect of canagliflozin relative to glimepiride on WBC counts. Materials and Methods: This was a post-hoc subanalysis of the CANDLE trial (Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial; UMIN000017669), an investigator-initiated, multicenter, open-label, randomized, controlled trial. A total of 233 patients with type 2 diabetes and concomitant heart failure were randomly assigned to either canagliflozin (n = 113) or glimepiride (n = 120) treatment for 24 weeks. Overall, patient baseline characteristics were as follows: mean ± standard deviation age, 68.6 ± 10.1 years; hemoglobin A1c, 7.0 ± 0.9%; left ventricular ejection fraction, 56.7 ± 14.4%; and median N-terminal pro-brain natriuretic peptide, 252 pg/mL (interquartile range 96–563 pg/mL). The mean baseline WBC counts were 6704 cells/μL (95% confidence interval 6,362–7,047) in the canagliflozin group and 6322 cells/μL (95% confidence interval 5,991–6,654) in the glimepiride group. There were no significant differences between treatment groups in terms of changes in WBC counts from baseline to weeks 4 and 12. In contrast, a group difference (canagliflozin minus glimepiride) from baseline to week 24 was significant (mean difference − 456 cells/μL [95% confidence interval −774 to −139, P = 0.005]). Conclusions: Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure

Amateur Observers Witness the Return of Venus’ Cloud Discontinuity

Firstly identified in images from JAXA’s orbiter Akatsuki, the cloud discontinuity of Venus is a planetary-scale phenomenon known to be recurrent since, at least, the 1980s. Interpreted as a new type of Kelvin wave, this disruption is associated to dramatic changes in the clouds’ opacity and distribution of aerosols, and it may constitute a critical piece for our understanding of the thermal balance and atmospheric circulation of Venus. Here, we report its reappearance on the dayside middle clouds four years after its last detection with Akatsuki/IR1, and for the first time, we characterize its main properties using exclusively near-infrared images from amateur observations. In agreement with previous reports, the discontinuity exhibited temporal variations in its zonal speed, orientation, length, and its effect over the clouds’ albedo during the 2019/2020 eastern elongation. Finally, a comparison with simultaneous observations by Akatsuki UVI and LIR confirmed that the discontinuity is not visible on the upper clouds’ albedo or thermal emission, while zonal speeds are slower than winds at the clouds’ top and faster than at the middle clouds, evidencing that this Kelvin wave might be transporting momentum up to upper clouds.Junta de Andalucía EMERGIA20_00414European Research Council (ERC) 772086Japan Society for the Promotion of Science (JSPS) JP21J0035

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure : a sub analysis of the CANDLE trial

Background: Identification of the effective subtypes of treatment for heart failure (HF) is an essential topic for optimizing treatment of the disorder. We hypothesized that the beneficial effect of SGLT2 inhibitors (SGLT2i) on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) might depend on baseline diastolic function. To elucidate the effects of SGLT2i in type 2 diabetes mellitus (T2DM) and chronic HF we investigated, as a post-hoc sub-study of the CANDLE trial, the effects of canagliflozin on NT-proBNP levels from baseline to 24 weeks, with the data stratified by left ventricular (LV) diastolic function at baseline. Methods: Patients (n = 233) in the CANDLE trial were assigned randomly to either an add-on canagliflozin (n = 113) or glimepiride treatment groups (n = 120). The primary endpoint was a comparison between the two groups of the changes from baseline to 24 weeks in NT-pro BNP levels, stratified according to baseline ventricular diastolic function. Results: The change in the geometric mean of NT-proBNP level from baseline to 24 weeks was 0.98 (95% CI 0.89–1.08) in the canagliflozin group and 1.07 (95% CI 0.97–1.18) in the glimepiride group. The ratio of change with canagliflozin/glimepiride was 0.93 (95% CI 0.82–1.05). Responder analyses were used to investigate the response of an improvement in NT-proBNP levels. Although the subgroup analyses for septal annular velocity (SEP-e′) showed no marked heterogeneity in treatment effect, the subgroup with an SEP-e′ < 4.7 cm/s indicated there was an association with lower NT-proBNP levels in the canagliflozin group compared with that in the glimepiride group (ratio of change with canagliflozin/glimepiride (0.83, 95% CI 0.66–1.04). Conclusions: In the subgroup with a lower LV diastolic function, canagliflozin showed a trend of reduced NT-pro BNP levels compared to that observed with glimepiride. This study suggests that the beneficial effects of canagliflozin treatment may be different in subgroups classified by the severity of LV diastolic dysfunction